Valuation: Biogen Inc.

Market Cap 30.86B 26.74B 25.05B 22.85B 42.96B 2,944B 43.62B 295B 115B 1,474B 116B 113B 4,915B P/E 2026 *
37.1x
P/E 2027 * 18.3x
Enterprise Value 35.8B 31.02B 29.06B 26.51B 49.83B 3,414B 50.6B 342B 134B 1,710B 134B 131B 5,701B EV / Sales 2026 *
3.43x
EV / Sales 2027 * 3.13x
Free-Float
85.97%
Yield 2026 *
-
Yield 2027 * -
1 day+2.03%
1 week+3.03%
Current month+2.62%
1 month+2.81%
3 months+6.64%
6 months+9.31%
Current year+21.41%
1 week 175.9
Extreme 175.9
182.06
1 month 165.54
Extreme 165.54
189.72
Current year 134.7
Extreme 134.7
193
1 year 113.3
Extreme 113.3
193
3 years 99
Extreme 99
255.4
5 years 99
Extreme 99
317.45
10 years 99
Extreme 99
351.7
Manager TitleAgeSince
Chief Executive Officer 66 14/11/2022
Director of Finance/CFO 60 01/03/2025
Chief Tech/Sci/R&D Officer - 28/10/2024
Director TitleAgeSince
Director/Board Member 69 23/03/2010
Director/Board Member 77 01/01/2010
Director/Board Member 72 19/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
+2.21%+3.03% - - 30.86B
+1.61%+4.60%+43.82%-0.10% 79.68B
+0.97%+4.90%-0.37%+26.99% 50.61B
-1.22%-2.62%+15.13%+166.74% 48.81B
-0.66%+5.25%-47.97%-48.32% 46.91B
+0.73%+2.10%+55.80%-22.78% 30.86B
+0.73%+20.01%+140.37%-35.36% 25.42B
-0.29%+2.00%+40.66%+85.09% 24.48B
-0.42%+5.37%+8.99%+187.03% 21.2B
-2.22%-0.42%+63.66%+161.33% 16.39B
Average +0.10%+3.36%+35.56%+57.85% 38.26B
Weighted average by Cap. +0.30%+2.91%+27.53%+41.59%

Financials

2026 *2027 *
Net sales 10.43B 9.04B 8.47B 7.72B 14.52B 995B 14.74B 99.6B 38.93B 498B 39.17B 38.32B 1,661B 10.64B 9.21B 8.63B 7.87B 14.8B 1,014B 15.03B 102B 39.69B 508B 39.93B 39.06B 1,694B
Net income 953M 826M 774M 706M 1.33B 90.9B 1.35B 9.1B 3.56B 45.52B 3.58B 3.5B 152B 1.9B 1.65B 1.54B 1.41B 2.64B 181B 2.68B 18.13B 7.09B 90.7B 7.13B 6.98B 302B
Net Debt 4.94B 4.28B 4.01B 3.66B 6.87B 471B 6.98B 47.13B 18.42B 236B 18.54B 18.13B 786B 2.42B 2.1B 1.96B 1.79B 3.37B 231B 3.42B 23.11B 9.03B 116B 9.09B 8.89B 385B
Logo Biogen Inc.
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (72%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (7.4%) ; - other (20.6%): primarily revenues from partnership agreements.
Employees
7,500
Date Price Change Volume
13/08/26 182.06 +1.99% 1
12/08/26 €178.50 +0.19% 100
11/08/26 €178.16 -1.07% 2
10/08/26 €180.08 +1.58% 139
07/08/26 €177.28 +0.33% 158
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
36
Last Close Price
208.87USD
Average target price
235.57USD
Spread / Average Target
+12.79%

Quarterly revenue - Rate of surprise